Seeking Alpha HealthcareOriginal article
Glaukos' iDose TR meets primary goal in phase 4 trial
Phase 3positiveiDose TRPositive
AI Analysis
Summary
Glaukos' iDose TR met its primary goal in a phase 4 trial, indicating successful advancement in the drug development program.
Clinical Trial Data
Phase
4
Primary Endpoint
Met
Outcome Details
Met primary goal in phase 4 trial
Importance:6/10
Sentiment:
0.70
clinical trialphase 4primary endpoint
Related Companies
Read the original article
Published by Seeking Alpha Healthcare on October 9, 2026 4:10 PM